Solid Tumor Targeting CAR-T Development Service: Switch Receptor

Online Inquiry

Background Service What We Can Offer Workflow Highlights Published data FAQs Contact

Creative Biolabs provides a specialized Solid Tumor Targeting CAR-T Development Service: Switch Receptor, designed to help researchers overcome the immunosuppressive tumor microenvironment (TME) that limits conventional CAR-T efficacy. By converting inhibitory signals such as TGF-β, IL-4, IL-10, or PD-L1 into activating cues, switch receptor–engineered CAR-T cells gain enhanced persistence, cytotoxicity, and adaptability in hostile solid tumor niches. This platform supports projects seeking stronger in vivo functionality, improved T-cell fitness, and durable tumor clearance.

Introduction

Solid tumors secrete high levels of inhibitory cytokines (e.g., TGF-β, IL-4, IL-10) and express checkpoint ligands (e.g., PD-L1) that suppress T-cell proliferation and cytotoxicity. The Switch Receptor strategy reprograms these suppressive cues into activation signals, enabling CAR-T cells to thrive even in a hostile TME.

Service

Switch receptors enable a proactive reprogramming of the TME by inverting suppressive signals into stimulatory cascades. Creative Biolabs integrates this approach into a comprehensive development pipeline:

Precision Molecular Design & Engineering

Our teams design modular switch receptors that fuse ligand-binding domains with potent costimulatory endodomains. These constructs help ensure CAR-T activation even in cytokine-rich, immunosuppressive tumor beds. Projects requiring high-fidelity customization, dual-switch combinations, or tumor-specific activation logic benefit from our rational architecture design and codon-optimized constructs.

Validated Functional Assessment Workflows

Each engineered CAR-T candidate undergoes rigorous functional evaluation, including resistance to TGF-β/IL-4 suppression, PD-L1–induced activation profiling, and assays measuring cytokine secretion, proliferation, and exhaustion marker reduction. These data-supported workflows provide evidence-driven decisions for pipeline advancement.

Strong Support for IND-Enabling Development

Creative Biolabs assists with translational-scale production, safety modules, and documentation tailored for regulatory submission. Teams planning to progress toward animal studies often rely on our experience across solid tumor models, including orthotopic and TME-integrated xenografts.

Discover How We Can Help - Request a Consultation.

Our Components on Switch Receptor Design Strategy

Technology Components of Switch Receptor. (Creative Biolabs Original)

Engineering Workflow in Our Service

The required starting materials include target tumor information detailing suppressive ligand expression, detailed project goals specifying car constructs and efficacy requirements, and source material specifications for T-cells or cell lines.

Workflow of Switch Receptor. (Creative Biolabs Original)

Key Advantages

Overcome Immunosuppression: Directly invert tumor-derived suppressive signals into T-cell activation.
Enhanced Persistence & Expansion: Switch receptors create continuous self-boosting stimulation inside TME.
Reduced Reliance on Exogenous Cytokines: Minimizes need for systemic IL-2 or adjuvants.
High Safety & Precision: Customizable logic-gate designs restrict activity to tumor sites.

Data Support

This study addresses two major limitations of CAR-T cell therapy: its toxicity to healthy tissues and the poor persistence of the therapeutic cells. The researchers developed an innovative switch receptor called T3/28. CAR-T cells equipped with this receptor showed reduced exhaustion, enhanced proliferation, and significantly longer-lasting anti-tumor activity in a mouse model of lymphoma, offering a promising strategy to improve the durability and safety of this cancer treatment.

Engineered switch receptors for enhanced CAR-T cell cytotoxicity (OA Literature)
Fig.1 Switch receptors to enhance the cytotoxicity of CAR-T cells.¹

FAQs

How do switch receptors improve CAR-T performance in solid tumors?

Switch receptors convert suppressive ligands into activating signals, enabling CAR-T cells to proliferate and function within cytokine-rich TME conditions. This strategy benefits projects struggling with T-cell exhaustion or weak persistence.

Can switch receptors be combined with standard CAR architectures or other enhancements?

Yes. They are compatible with second and third-generation CARs and can operate alongside cytokine armoring, checkpoint-resistant designs, or logic-gated systems. Teams exploring multi-modality engineering can request integrated design recommendations.

What tumor types are most suitable for switch receptor–based CAR-T therapy?

Tumors with high levels of TGF-β, IL-4, IL-10, or PD-L1 expression, such as pancreatic, lung, colorectal, and ovarian cancers, show strong potential. Creative Biolabs can help evaluate ligand expression profiles to guide construct selection.

Partner with Us

Creative Biolabs provides a full suite of capabilities for Solid Tumor Targeting CAR-T Development using Switch Receptors, including custom receptor construction, comprehensive functional testing, and translational support. This service empowers research teams to overcome TME challenges and advance more potent CAR-T candidates. For personalized guidance, contact our scientific team at any stage to discuss your study's needs.

Reference

Zhao, Songbo et al. “Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells.” Journal for immunotherapy of cancer vol. 9,12 (2021). Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1136/jitc-2021-003176

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.